Jerusalem Pharmaceuticals Co. Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported sales of USD 8,963,638 as compared to USD 8,418,052 reported in the same period a year ago. Net income after tax was USD 759,253 as compared to USD 1,188,800 reported a year ago. Basic and diluted loss per share were USD 0.046 as compared to USD 0.066 a year ago.